Mark A. Velleca - Feb 14, 2024 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
PRESIDENT & CEO, Director
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Stock symbol
BDTX
Transactions as of
Feb 14, 2024
Transactions value $
$0
Form type
4
Date filed
2/15/2024, 05:35 PM
Previous filing
Sep 18, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Award $0 +537K $0.00 537K Feb 14, 2024 Common Stock 537K $4.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter.